![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Adds Dexamethasone to COVID-19 Temporary Compounding Lists
FDA Adds Dexamethasone to COVID-19 Temporary Compounding Lists
![Dexamethasone](https://www.fdanews.com/ext/resources/test/Drug-Images4/Dexamethasone.gif?t=1594856960&width=430)
July 16, 2020
The FDA has added dexamethasone to the list of drugs that may be compounded under its temporary policy allowing compounders to produce the drug during the COVID-19 pandemic.
Demand for the anti-inflammatory drug surged in mid-June after UK researchers reported that it reduced deaths in critically ill COVID-19 patients.
Five suppliers of dexamethasone are currently on the FDA’s drug shortages list — AuroMedics Pharma, Fresenius Kabi USA, Hikma Pharmaceuticals USA, Mylan Institutional and Somerset Therapeutics.
Upcoming Events
-
21Oct